Ion Channel Drug Discovery
2 contributors - Hardback
£175.00
Brian Cox is currently the UK Head of Chemistry for Novartis Institutes of BioMedical Research (NIBR). He has 26 years of experience in drug discovery, working in many therapeutic areas, but particularly in the respiratory and gastrointestinal areas. He is a specialist in the discovery of modulators of ion channels, associated with the development of a number of compounds that have entered evaluation in man. Brian has an extensive publication, presentation and patent record and is a member of the RSC BMCS committee, and he recently co-organised a joint meeting of the BMCS and British Pharmacological Society entitled "Ion Channels as Therapeutic Targets". He is also a Fellow of the Royal Society of Chemistry, is a Chartered Scientist and Chartered Chemist and a Member of the Royal Pharmaceutical Society of Great Britain. Martin Gosling is currently Head of the Ion Channel Unit, Respiratory Diseases Area, Novartis Institutes of BioMedical Research (NIBR). With a PhD in ion channel pharmacology, he has 8 years experience in ion channel drug discovery in a pharmaceutical setting. He is also a Tenured Lecturer at Imperial College School of Medicine with research emphasis on ion channel function in vasculature. Martin has an extensive publication record in the ion channel area with numerous invited presentations at international meetings. He has been an organiser/session chair of multiple international ion channel conferences including the recent joint BMCS and British Pharmacological Society "Ion Channels as Therapeutic Targets" symposium.